RU2666144C2 - Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты - Google Patents

Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты Download PDF

Info

Publication number: RU2666144C2
Authority: RU; Russia
Prior art keywords: compound; diffraction pattern; chlorophenoxy; cyano; acetic acid
Prior art date: 2013-01-24

Application number

RU2015134420A

Other languages

English (en)

Russian (ru)

Other versions

RU2015134420A (ru

Inventor

Клаудия ВИТШИ

Майкл Д. Томпсон

Юн Мин ПАРК

Майкл П. АРЕНД

Original Assignee

Фиброген, Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-24

Filing date

2014-01-23

Publication date

2018-09-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2666144(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-01-23 Application filed by Фиброген, Инк. filed Critical Фиброген, Инк.

2017-03-03 Publication of RU2015134420A publication Critical patent/RU2015134420A/ru

2018-09-06 Application granted granted Critical

2018-09-06 Publication of RU2666144C2 publication Critical patent/RU2666144C2/ru

Links

URLWARYNFTXXFV-UHFFFAOYSA-N 2-[[5-(4-chlorophenoxy)-1-cyano-4-hydroxyisoquinoline-3-carbonyl]amino]acetic acid Chemical compound C12=C(O)C(C(=O)NCC(=O)O)=NC(C#N)=C2C=CC=C1OC1=CC=C(Cl)C=C1 URLWARYNFTXXFV-UHFFFAOYSA-N 0.000 title claims abstract description 36
229940126062 Compound A Drugs 0.000 claims abstract description 235
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract description 235
239000000203 mixture Substances 0.000 claims abstract description 96
238000000034 method Methods 0.000 claims abstract description 86
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 43
102000003951 Erythropoietin Human genes 0.000 claims abstract description 38
108090000394 Erythropoietin Proteins 0.000 claims abstract description 38
229940105423 erythropoietin Drugs 0.000 claims abstract description 38
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims abstract description 38
208000007502 anemia Diseases 0.000 claims abstract description 37
239000000126 substance Substances 0.000 claims abstract description 21
206010021143 Hypoxia Diseases 0.000 claims abstract description 11
230000007954 hypoxia Effects 0.000 claims abstract description 10
238000000634 powder X-ray diffraction Methods 0.000 claims description 96
238000010438 heat treatment Methods 0.000 claims description 46
238000001938 differential scanning calorimetry curve Methods 0.000 claims description 27
238000000113 differential scanning calorimetry Methods 0.000 claims description 22
238000001816 cooling Methods 0.000 claims description 17
230000005855 radiation Effects 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 10
239000002775 capsule Substances 0.000 claims description 9
238000002955 isolation Methods 0.000 claims description 8
230000001404 mediated effect Effects 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 abstract description 26
230000000694 effects Effects 0.000 abstract description 17
239000000843 powder Substances 0.000 abstract description 8
238000009472 formulation Methods 0.000 abstract description 7
230000008901 benefit Effects 0.000 abstract description 4
230000001939 inductive effect Effects 0.000 abstract 1
239000007787 solid Substances 0.000 description 49
150000001875 compounds Chemical class 0.000 description 28
239000000546 pharmaceutical excipient Substances 0.000 description 28
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
239000000523 sample Substances 0.000 description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
239000003814 drug Substances 0.000 description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
229940079593 drug Drugs 0.000 description 19
239000002904 solvent Substances 0.000 description 19
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
108010054147 Hemoglobins Proteins 0.000 description 18
102000001554 Hemoglobins Human genes 0.000 description 18
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 18
239000012453 solvate Substances 0.000 description 18
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
210000003743 erythrocyte Anatomy 0.000 description 15
238000002411 thermogravimetry Methods 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 14
238000005534 hematocrit Methods 0.000 description 14
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
238000005481 NMR spectroscopy Methods 0.000 description 13
230000008569 process Effects 0.000 description 13
239000000243 solution Substances 0.000 description 13
238000001356 surgical procedure Methods 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
208000035475 disorder Diseases 0.000 description 12
238000010992 reflux Methods 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 11
229940011051 isopropyl acetate Drugs 0.000 description 11
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical group CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
239000000725 suspension Substances 0.000 description 11
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
239000004471 Glycine Substances 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
230000032683 aging Effects 0.000 description 9
201000010099 disease Diseases 0.000 description 9
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
208000020832 chronic kidney disease Diseases 0.000 description 8
239000013078 crystal Substances 0.000 description 8
238000000354 decomposition reaction Methods 0.000 description 8
208000028867 ischemia Diseases 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
238000004113 cell culture Methods 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
ZKGWLOQMZOXQDF-UHFFFAOYSA-N ethyl 5-(4-chlorophenoxy)-1-cyano-4-hydroxyisoquinoline-3-carboxylate Chemical compound C12=C(O)C(C(=O)OCC)=NC(C#N)=C2C=CC=C1OC1=CC=C(Cl)C=C1 ZKGWLOQMZOXQDF-UHFFFAOYSA-N 0.000 description 7
210000003734 kidney Anatomy 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
238000005160 1H NMR spectroscopy Methods 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000004807 desolvation Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
238000013059 nephrectomy Methods 0.000 description 6
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
238000001757 thermogravimetry curve Methods 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
238000012512 characterization method Methods 0.000 description 5
230000002596 correlated effect Effects 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
239000008298 dragée Substances 0.000 description 5
238000001035 drying Methods 0.000 description 5
230000000302 ischemic effect Effects 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
238000002156 mixing Methods 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
210000001995 reticulocyte Anatomy 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
-1 structures Natural products 0.000 description 5
239000003826 tablet Substances 0.000 description 5
208000030760 Anaemia of chronic disease Diseases 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
206010007559 Cardiac failure congestive Diseases 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
206010019280 Heart failures Diseases 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
208000022400 anemia due to chronic disease Diseases 0.000 description 4
239000003173 antianemic agent Substances 0.000 description 4
206010003246 arthritis Diseases 0.000 description 4
238000004820 blood count Methods 0.000 description 4
238000000576 coating method Methods 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
229940126534 drug product Drugs 0.000 description 4
229940125367 erythropoiesis stimulating agent Drugs 0.000 description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
230000002489 hematologic effect Effects 0.000 description 4
208000014674 injury Diseases 0.000 description 4
229910052742 iron Inorganic materials 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
238000012545 processing Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
239000000600 sorbitol Substances 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
108010011485 Aspartame Proteins 0.000 description 3
208000017667 Chronic Disease Diseases 0.000 description 3
229930091371 Fructose Natural products 0.000 description 3
239000005715 Fructose Substances 0.000 description 3
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 3
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 3
229920002774 Maltodextrin Polymers 0.000 description 3
239000005913 Maltodextrin Substances 0.000 description 3
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
108010074633 Mixed Function Oxygenases Proteins 0.000 description 3
102000008109 Mixed Function Oxygenases Human genes 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
208000010378 Pulmonary Embolism Diseases 0.000 description 3
206010063837 Reperfusion injury Diseases 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
238000010171 animal model Methods 0.000 description 3
235000010357 aspartame Nutrition 0.000 description 3
239000000605 aspartame Substances 0.000 description 3
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
229960003438 aspartame Drugs 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
208000022831 chronic renal failure syndrome Diseases 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
230000000913 erythropoietic effect Effects 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229940014259 gelatin Drugs 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000000227 grinding Methods 0.000 description 3
102000044890 human EPO Human genes 0.000 description 3
229910052738 indium Inorganic materials 0.000 description 3
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
229940035034 maltodextrin Drugs 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
239000008247 solid mixture Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
231100000397 ulcer Toxicity 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
108010044267 Abnormal Hemoglobins Proteins 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010054936 Cardiac cirrhosis Diseases 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
229920002148 Gellan gum Polymers 0.000 description 2
206010050789 Hypochromasia Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
206010022657 Intestinal infarction Diseases 0.000 description 2
108010035210 Iron-Binding Proteins Proteins 0.000 description 2
102000008133 Iron-Binding Proteins Human genes 0.000 description 2
208000032382 Ischaemic stroke Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
206010027540 Microcytosis Diseases 0.000 description 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
108010043005 Prolyl Hydroxylases Proteins 0.000 description 2
102000004079 Prolyl Hydroxylases Human genes 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
229930003779 Vitamin B12 Natural products 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000004159 blood analysis Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010418 carrageenan Nutrition 0.000 description 2
229920001525 carrageenan Polymers 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
239000006071 cream Substances 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000013480 data collection Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
229960000304 folic acid Drugs 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
235000010492 gellan gum Nutrition 0.000 description 2
239000000216 gellan gum Substances 0.000 description 2
239000003349 gelling agent Substances 0.000 description 2
239000007902 hard capsule Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229910000358 iron sulfate Inorganic materials 0.000 description 2
BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
238000011694 lewis rat Methods 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000008183 oral pharmaceutical preparation Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000010926 purge Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
238000003756 stirring Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
230000007704 transition Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
235000019163 vitamin B12 Nutrition 0.000 description 2
239000011715 vitamin B12 Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
229920001285 xanthan gum Polymers 0.000 description 2
235000010493 xanthan gum Nutrition 0.000 description 2
239000000230 xanthan gum Substances 0.000 description 2
229940082509 xanthan gum Drugs 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000408896 Alenia Species 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
102100037249 Egl nine homolog 1 Human genes 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
101000881648 Homo sapiens Egl nine homolog 1 Proteins 0.000 description 1
101000881650 Homo sapiens Prolyl hydroxylase EGLN2 Proteins 0.000 description 1
101000881678 Homo sapiens Prolyl hydroxylase EGLN3 Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
206010022971 Iron Deficiencies Diseases 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
208000036696 Microcytic anaemia Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 description 1
102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 description 1
238000001069 Raman spectroscopy Methods 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
206010063897 Renal ischaemia Diseases 0.000 description 1
241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
206010040943 Skin Ulcer Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000001744 Sodium fumarate Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
206010001053 acute respiratory failure Diseases 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940023476 agar Drugs 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
238000012742 biochemical analysis Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
229940068682 chewable tablet Drugs 0.000 description 1
201000002816 chronic venous insufficiency Diseases 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
238000012937 correction Methods 0.000 description 1
229910052593 corundum Inorganic materials 0.000 description 1
239000010431 corundum Substances 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
238000013481 data capture Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
238000009509 drug development Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
230000010437 erythropoiesis Effects 0.000 description 1
SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
101150070966 eta gene Proteins 0.000 description 1
LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
229910052732 germanium Inorganic materials 0.000 description 1
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008202 granule composition Substances 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
208000006278 hypochromic anemia Diseases 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002505 iron Chemical class 0.000 description 1
230000010438 iron metabolism Effects 0.000 description 1
208000037906 ischaemic injury Diseases 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
239000003380 propellant Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000012950 reanalysis Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
229910052594 sapphire Inorganic materials 0.000 description 1
239000010980 sapphire Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019294 sodium fumarate Nutrition 0.000 description 1
229940005573 sodium fumarate Drugs 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000001752 temperature-resolved X-ray diffraction Methods 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002076 thermal analysis method Methods 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000002966 varnish Substances 0.000 description 1
201000002282 venous insufficiency Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

RU2015134420A 2013-01-24 2014-01-23 Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты RU2666144C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361756361P	2013-01-24	2013-01-24
US61/756,361		2013-01-24
PCT/US2014/012780 WO2014116849A1 (fr)	2013-01-24	2014-01-23	Formes cristallines d'acide {[1-cyano-5-(4-chlorophénoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acétique

Publications (2)

Publication Number	Publication Date
RU2015134420A RU2015134420A (ru)	2017-03-03
RU2666144C2 true RU2666144C2 (ru)	2018-09-06

Family

ID=50073508

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2015134420A RU2666144C2 (ru)	2013-01-24	2014-01-23	Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты

Country Status (15)

Country	Link
US (1)	US9643928B2 (fr)
EP (1)	EP2951159B1 (fr)
JP (1)	JP6437456B2 (fr)
KR (1)	KR102233081B1 (fr)
CN (1)	CN105452227B (fr)
AU (1)	AU2014209319B2 (fr)
CA (1)	CA2899024C (fr)
DK (1)	DK2951159T3 (fr)
ES (1)	ES2694297T3 (fr)
IL (1)	IL240066B (fr)
MX (1)	MX360048B (fr)
RU (1)	RU2666144C2 (fr)
SG (2)	SG11201505748UA (fr)
TW (1)	TWI685487B (fr)
WO (1)	WO2014116849A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1644336T3 (da)	2003-06-06	2011-05-09	Fibrogen Inc	Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
AU2009314155B2 (en)	2008-11-14	2015-10-08	Fibrogen, Inc.	Thiochromene derivatives as HIF hydroxylase inhibitors
CA2879242C (fr)	2012-07-16	2023-05-09	Fibrogen, Inc.	Formes cristallines d'un inhibiteur de prolyle hydroxylase de l'acide [(4-hydroxy-1-methyl-7-phenoxy-isoquinoleine-3-carbonyle)-amino]-acetique
CA2879238C (fr)	2012-07-16	2021-08-10	Fibrogen, Inc.	Procede de fabrication de composes isoquinoleine
US8883823B2 (en)	2012-07-16	2014-11-11	Fibrogen, Inc.	Crystalline forms of a prolyl hydroxylase inhibitor
MX360048B (es)	2013-01-24	2018-10-19	Fibrogen Inc	Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
CN105377242A (zh)	2013-06-06	2016-03-02	菲布罗根有限公司	Hif羟化酶抑制剂的药物制剂
CN105384687B (zh)	2014-09-02	2018-05-01	广东东阳光药业有限公司	喹啉酮类化合物及其在药物中应用
EP4121009A4 (fr) *	2020-03-17	2024-04-17	Zydus Lifesciences Limited	Formulation comprenant des inhibiteurs de hif prolyl hydroxylase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009075826A1 (fr) *	2007-12-07	2009-06-18	Fibrogen, Inc.	Procédés pour augmenter le taux des leucocytes
RU2379291C2 (ru) *	2003-06-06	2010-01-20	Фиброген, Инк.	Азотсодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина
US7928120B2 (en) *	2006-01-27	2011-04-19	Fibrogen, Inc.	Cyanoisoquinoline compounds and methods of use thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4036964A (en)	1973-10-11	1977-07-19	Beecham Group Limited	Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en)	1973-10-30	1976-11-02	Sandoz, Inc.	3-Substituted-4-aryl isoquinolines
DE2818423A1 (de)	1978-04-27	1979-11-08	Hoechst Ag	Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de)	1982-09-09	1984-03-15	Hoechst Ag, 6230 Frankfurt	Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4559403A (en)	1983-05-19	1985-12-17	Hoffmann-La Roche Inc.	Substituted isoquinolines
US4584379A (en)	1985-01-22	1986-04-22	Merrell Dow Pharmaceuticals Inc.	Isoquinoline thromboxane synthetase inhibitors
US4822800A (en)	1986-06-09	1989-04-18	Ortho Pharmaceutical Corporation	Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4952588A (en)	1987-11-27	1990-08-28	Hoechst-Roussel Pharmaceuticals Inc.	1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en)	1987-11-27	1990-10-30	Hoechst-Roussel Pharmaceuticals Inc.	1-aryl-3-isoquinolinecarboxamides
EP0532466A3 (en)	1991-09-12	1993-06-16	Ciba-Geigy Ag	Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0626178A1 (fr)	1993-05-17	1994-11-30	Ciba-Geigy Ag	Utilisation d'inhibiteurs de la protease du VIH dans le traitement des maladies tumorales
DE59401923D1 (de)	1993-11-02	1997-04-10	Hoechst Ag	Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE59401924D1 (de)	1993-11-02	1997-04-10	Hoechst Ag	Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2138929A1 (fr)	1993-12-30	1995-07-01	Klaus Weidmann	Carboxamides heterocycliques substitues, leur preparation et leur utilisation comme composes pharmaceutiques
US5563143A (en)	1994-09-21	1996-10-08	Pfizer Inc.	Catechol diether compounds as inhibitors of TNF release
WO1996018616A1 (fr)	1994-12-12	1996-06-20	Merck & Co., Inc.	2-aminopyridines substituees utilisees comme inhibiteurs de synthase d'oxyde d'azote
IL135495A (en)	1995-09-28	2002-12-01	Hoechst Ag	Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
IL129344A0 (en)	1996-11-27	2000-02-17	Du Pont Pharm Co	Novel integrin receptor antagonists
GB9707830D0 (en)	1997-04-18	1997-06-04	Smithkline Beecham Plc	Novel compounds
WO1998050346A2 (fr)	1997-04-18	1998-11-12	Smithkline Beecham Plc	Derives d'acetamide et d'uree, procede de preparation et utilisation de ces derives dans le traitement des troubles du systeme nerveux central
DE19746287A1 (de)	1997-10-20	1999-04-22	Hoechst Marion Roussel De Gmbh	Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr)	1998-06-22	1999-12-24	Centre Nat Rech Scient	Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it)	1998-10-15	2000-09-29	Zambon Spa	Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en)	1999-04-26	2000-11-10	Neurogen Corporation	2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it)	2000-02-09	2003-11-18	Rotta Research Lab	Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
US7622503B2 (en)	2000-08-24	2009-11-24	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
FI20002044A0 (fi)	2000-09-15	2000-09-15	Orion Yhtymae Oyj	Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AU2002241154A1 (en)	2001-03-21	2002-10-03	Isis Innovation Ltd.	Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
EP1401817A4 (fr)	2001-06-13	2005-11-02	Genesoft Pharmaceuticals Inc	Composes isoquinoline presentant une activite anti-infectieuse
US6716866B2 (en)	2001-06-13	2004-04-06	Genesoft Pharmaceuticals, Inc.	Aryl-benzimidazole compounds having antiinfective activity
US6841566B2 (en)	2001-07-20	2005-01-11	Boehringer Ingelheim, Ltd.	Viral polymerase inhibitors
EP2335700A1 (fr)	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
US7294457B2 (en)	2001-08-07	2007-11-13	Boehringer Ingelheim (Canada) Ltd.	Direct binding assay for identifying inhibitors of HCV polymerase
US6762318B2 (en)	2001-12-03	2004-07-13	Novo Nordisk A/S	Glucagon antagonists
US20030153503A1 (en)	2001-12-06	2003-08-14	Klaus Stephen J.	Methods of increasing endogenous erythropoietin (EPO)
GB0206711D0 (en)	2002-03-21	2002-05-01	Isis Innovation	HIF Inhibitor
US8124582B2 (en)	2002-12-06	2012-02-28	Fibrogen, Inc.	Treatment of diabetes
US7618940B2 (en)	2002-12-06	2009-11-17	Fibrogen, Inc.	Fat regulation
WO2005007192A2 (fr)	2003-06-06	2005-01-27	Fibrogen, Inc.	Cytoprotection
DK1644336T3 (da)	2003-06-06	2011-05-09	Fibrogen Inc	Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
US8614204B2 (en)	2003-06-06	2013-12-24	Fibrogen, Inc.	Enhanced erythropoiesis and iron metabolism
US20060173046A1 (en)	2003-07-15	2006-08-03	Bell Ian M	Hydroxypyridine cgrp receptor antagonists
JP2007501844A (ja)	2003-08-08	2007-02-01	トランス　テック　ファーマ，インコーポレイテッド	アリール及びヘテロアリール化合物、組成物並びに使用方法
US7208601B2 (en)	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
US7248053B2 (en)	2004-07-15	2007-07-24	Powerprecise Solutions, Inc.	One time operating state detecting method and apparatus
EP1676834A1 (fr)	2004-12-30	2006-07-05	Sanofi-Aventis Deutschland GmbH	Dérivés de carboxamide bicycliqués et fusionnés utiles comme des inhibiteurs de CXCR2 pour traiter l'inflammation
EP1866318B1 (fr)	2005-03-02	2011-06-22	Fibrogen, Inc.	Nouveaux composes a base de thienopyridine et procedes d'utilisation correspondants
EP1893186A2 (fr)	2005-06-06	2008-03-05	Fibrogen, Inc.	Methode amelioree de traitement de l'anemie
BRPI0611670A2 (pt)	2005-06-15	2016-11-16	Fibrogen Inc	método para o tratamento ou prevenção de câncer em um indivíduo
EP1991269A1 (fr) *	2006-02-16	2008-11-19	Fibrogen, Inc.	Composés et méthodes pour traiter un accident cérébrovasculaire
MX2008012734A (es)	2006-04-04	2009-01-29	Fibrogen Inc	Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif).
US20070293575A1 (en)	2006-06-15	2007-12-20	Fibrogen, Inc.	Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en)	2006-06-15	2010-05-11	Fibrogen, Inc.	Compounds and methods for treatment of chemotherapy-induced anemia
MX360048B (es)	2013-01-24	2018-10-19	Fibrogen Inc	Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.

2014
- 2014-01-23 MX MX2015009617A patent/MX360048B/es active IP Right Grant
- 2014-01-23 US US14/763,127 patent/US9643928B2/en not_active Expired - Fee Related
- 2014-01-23 SG SG11201505748UA patent/SG11201505748UA/en unknown
- 2014-01-23 EP EP14704030.7A patent/EP2951159B1/fr active Active
- 2014-01-23 WO PCT/US2014/012780 patent/WO2014116849A1/fr not_active Ceased
- 2014-01-23 KR KR1020157022614A patent/KR102233081B1/ko active Active
- 2014-01-23 CA CA2899024A patent/CA2899024C/fr active Active
- 2014-01-23 AU AU2014209319A patent/AU2014209319B2/en not_active Ceased
- 2014-01-23 DK DK14704030.7T patent/DK2951159T3/en active
- 2014-01-23 RU RU2015134420A patent/RU2666144C2/ru active
- 2014-01-23 TW TW103102462A patent/TWI685487B/zh not_active IP Right Cessation
- 2014-01-23 ES ES14704030.7T patent/ES2694297T3/es active Active
- 2014-01-23 CN CN201480016402.9A patent/CN105452227B/zh active Active
- 2014-01-23 SG SG10202009266PA patent/SG10202009266PA/en unknown
- 2014-01-23 JP JP2015555276A patent/JP6437456B2/ja not_active Expired - Fee Related
2015
- 2015-07-21 IL IL240066A patent/IL240066B/en unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2379291C2 (ru) *	2003-06-06	2010-01-20	Фиброген, Инк.	Азотсодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина
US7928120B2 (en) *	2006-01-27	2011-04-19	Fibrogen, Inc.	Cyanoisoquinoline compounds and methods of use thereof
WO2009075826A1 (fr) *	2007-12-07	2009-06-18	Fibrogen, Inc.	Procédés pour augmenter le taux des leucocytes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Caira M.R. и др.: "Crystalline polymorthism of organic compounds" TOPICS IN CURRENT CHEMISTRY, 198, 1998, стр.163-208, стр.165-166. *

Also Published As

Publication number	Publication date
AU2014209319A1 (en)	2015-08-27
MX360048B (es)	2018-10-19
CA2899024C (fr)	2022-01-04
US20160002170A1 (en)	2016-01-07
US9643928B2 (en)	2017-05-09
IL240066A0 (en)	2015-09-24
CN105452227A (zh)	2016-03-30
JP2016505071A (ja)	2016-02-18
ES2694297T3 (es)	2018-12-19
EP2951159B1 (fr)	2018-08-22
CA2899024A1 (fr)	2014-07-31
TW201444800A (zh)	2014-12-01
CN105452227B (zh)	2018-05-29
HK1217331A1 (en)	2017-01-06
JP6437456B2 (ja)	2018-12-12
MX2015009617A (es)	2016-04-20
WO2014116849A1 (fr)	2014-07-31
EP2951159A1 (fr)	2015-12-09
SG10202009266PA (en)	2020-10-29
KR102233081B1 (ko)	2021-03-29
TWI685487B (zh)	2020-02-21
IL240066B (en)	2019-08-29
SG11201505748UA (en)	2015-08-28
DK2951159T3 (en)	2018-11-19
AU2014209319B2 (en)	2018-04-19
RU2015134420A (ru)	2017-03-03
KR20150129679A (ko)	2015-11-20

Publication	Publication Date	Title
RU2666144C2 (ru)	2018-09-06	Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты
AU2013290438C1 (en)	2019-01-03	Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
US9918977B2 (en)	2018-03-20	Crystalline forms of a prolyl hydroxylase inhibitor
HK1217331B (en)	2019-10-04	Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
HK40077210A (en)	2023-03-03	Crystalline forms of a prolyl hydroxylase inhibitor
HK40006583B (en)	2022-08-19	Crystalline forms of a prolyl hydroxylase inhibitor
HK1241365B (en)	2019-08-02	Crystalline forms of a prolyl hydroxylase inhibitor